A Medsky Topics feed composed of posts covering recent news related to GLP-1 Agonists such as Semaglutide (Ozempic, Wegovy, Rybelsus), Liraglutide (Victoza), and Tirzepatide (Zepbound, Mounjaro) Powered by @medsky.network
Feed on Bluesky
www.washingtonpost.com
Some people are getting shut out when it comes to GLP-1 drugs. Here’s why.
A third of state Medicaid programs paid for the drugs for weight loss as of mid-2025. This year it's about one in five, according to a review by The Washington Post.
www.mirror.co.uk
The 'life-changing' side effect for women from Mounjaro and Wegovy
bit.ly
Losing Pounds, Not Gaining Steps – Sajana Maharjan
Step Counts Drop Among GLP-1 Users People who lost weight with GLP...
thehill.com
GLP-1 drugs could reduce long-term sick leave: Study
Based on Danish data, the study found those on GLP-1s had 17% less long-term absences.
dlvr.it
Glucagon-Like Peptide-1 Receptor Agonist and Age-related Macular Degeneration: Adding to the Story
Since the approval of semaglutide for treatment of type 2 diabetes in 2017, use of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) has skyrocketed with 12% of adults reporting having taken the drugs.1 In addition to the treatment of diabetes, the US Food and Drug Administration has approved semaglutide for the treatment of obesity, cardiovascular disease, and metabolic dysfunction–associated steatohepatitis. Furthermore, trials are ongoing for diverse indications, such as drug and alcohol addiction, psoriasis, Parkinson’s disease, and acute pulmonary embolism, supported by a variety of mechanisms of action.
www.theguardian.com
Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic
dlvr.it
FDA committee recommends looser restrictions for several peptides
An FDA committee is recommending the addition of several peptides to the 503A bulk drug substances list. The FDA’s Pharmacy Compounding Advisory Committee, which has faced scrutiny for having several members with conflicts of interest, met July 23 and 24 to discuss peptides. Owais Durrani, DO, an emergency medicine physician in Houston, previously wrote for Healio that “some of the most transformative drugs in modern medicine are peptides,” including insulin and semaglutide. While “the science of peptides is real, serious and worth pursuing,” Durrani wrote, the current system is messy: “a
dlvr.it
FDA committee recommends looser restrictions for several peptides
An FDA committee is recommending the addition of several peptides to the 503A bulk drug substances list. The FDA’s Pharmacy Compounding Advisory Committee, which has faced scrutiny for having several members with conflicts of interest, met July 23 and 24 to discuss peptides. Owais Durrani, DO, an emergency medicine physician in Houston, previously wrote for Healio that “some of the most transformative drugs in modern medicine are peptides,” including insulin and semaglutide. While “the science of peptides is real, serious and worth pursuing,” Durrani wrote, the current system is messy: “a
www.theguardian.com
Tell us: what impact have GLP-1s had on your relationships?
bit.ly
Ozempic maker Novo Nordisk takes biggest rival to court over weight loss drug ads
Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs.
buff.ly
‘The Pitt’ showed us the stigma patients with obesity face. Massachusetts policies cutting GLP-1 drug coverage reflect the same biases.
Policymakers must work with insurers and GLP-1 manufacturers to make sure these life-changing therapies remain accessible. Blanket denials of coverage will harm patients, invite long-term costs, and…
www.irishstar.com
Rosie O'Donnell says 'Mounjaro saved my life' after 60lb weight loss
www.mercurynews.com
Medicare’s new GLP-1 weight loss program is complicated but worth it
www.eastbaytimes.com
Medicare’s new GLP-1 weight loss program is complicated but worth it
www.independent.co.uk
New study links weight loss jabs to huge drop in alcohol-related hospital admissions
The analysis found GLP-1 drugs slashed the risk of alcohol-related hospital admission by 26% compared with other diabetes medicines
bit.ly
Should you microdose GLP-1 drugs for weight loss?
Possibly. But only under medical supervision
www.theguardian.com
Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic
TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorder * Follow our Australia news live blog for latest updates * Get our breaking news email, free app or daily news podcast Australia’s medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments – including Ozempic and Mounjaro – over the potential to cause a “rare but severe” eye disorder that could lead to blindness. The Therapeutic Goods Administration’s (TGA) warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, have been linked to 36 cases of the condition. Continue reading...
www.medpagetoday.com
New Study Links GLP-1s to Hair Loss
Absolute risk of alopecia was low, however
l.euronews.com
GLP-1 drugs linked to “low” but real risk of hair loss, study finds
People taking GLP-1 drugs have a low risk of hair loss, which is significantly higher than for those on other diabetes medications, a new study has found.
cnb.cx
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
www.bmj.com
GLP-1 diabetes drugs linked to increased risk of hair loss
Open access research
Medsky Topics